Elite Pharmaceuticals, Inc.
Elite enters second pilot Phase I trial of its once-daily oxycodone product
Published in Pharma Law Weekly, June 20th, 2006
This patent-pending product is intended to deliver more consistent levels of the drug to patients who take the drug for chronic pain. Currently, there is no once-daily oxycodone on the market.
This is the second study for ELI-154 and the company's second oxycodone HCl product in clinical trials. The first pilot Phase I study for this product demonstrated proof of concept. This second study will evaluate variables to optimize the formulation. Upon completion of this study, Elite intends to enter into a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
Source: Pharma Law Weekly (2006-06-20)
More Articles from Pharma Law Weekly
- Aegate
Pilot study confirms use of Aegate's technology to combat pharmaceutical fraud - Angiotech Pharmaceuticals, Inc.
Angiotech Pharmaceuticals to acquire Quill Medical - Biotechnology Industry Organization
BIO names Tom DiLenge as general counsel - Chimerix, Inc.
Chimerix acquires lead compound library of antiviral agents from University of Michigan - Elsevier MDL
Electronic laboratory notebooks for chemistry and biology are reviewed - ExonHit Therapeutics
ExonHit files patent on a panel of genes for the diagnosis of Alzheimer disease from blood - More from this issue of Pharma Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
